vunakizumab   Click here for help

GtoPdb Ligand ID: 9296

Synonyms: AnDajing (Chinese trade name) | SHR-1314
Approved drug Immunopharmacology Ligand
vunakizumab is an approved drug (China NMPA (2024))
Compound class: Antibody
Comment: Vunakizumab (SHR-1314) is an investigational, humanized monoclonal antibody targeting IL17A, with potential use in autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A patent literature search identifies peptide sequences in WO2015070697, which are identical matches to the heavy and light chain variable regions of vunakizumab (SEQ ID NO 5 and 9 respectively) [2]. These sequences belong to antibody coded Hu049.
No information available.
Summary of Clinical Use Click here for help
Vunakizumab (SHR-1314) was advanced to clinical evaluation in patients with psoriasis. First approval was granted in China in August 2024, to treat moderate-to-severe plaque psoriasis [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04121143 A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults Phase 2 Interventional Jiangsu HengRui Medicine Co., Ltd. Jiangsu Hengrui Medicine have suspended this trial; the reason is unclear.